Evobrutinib - Merck Serono

Drug Profile

Evobrutinib - Merck Serono

Alternative Names: M-2951; MSC 2364447; MSC2364447C

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Class Antirheumatics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I Autoimmune disorders

Most Recent Events

  • 14 Sep 2017 EMD Serono Research & Development Institute and Merck initiate enrolment in a phase IIb trial for Rheumatois arthritis (Adjunctive treatment) in USA (NCT03233230)
  • 25 Jul 2017 EMD Serono and Merck plan a phase IIb trial for Rheumatoid arthritis (In adults, In the elderly) in USA and Germany (PO) (NCT03233230)
  • 16 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top